Ziresovir Explained

Ziresovir (RO-0529, AK0529) is an antiviral drug which was developed as a treatment for respiratory syncytial virus. It acts as a fusion inhibitor, and has shown good results in Phase II and III clinical trials.[1] [2] [3]

See also

Notes and References

  1. Zheng X, Gao L, Wang L, Liang C, Wang B, Liu Y, Feng S, Zhang B, Zhou M, Yu X, Xiang K, Chen L, Guo T, Shen HC, Zou G, Wu JZ, Yun H . 6 . Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor . Journal of Medicinal Chemistry . 62 . 13 . 6003–6014 . July 2019 . 31194544 . 10.1021/acs.jmedchem.9b00654 . free .
  2. Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC . Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference . Antiviral Research . 167 . 45–67 . July 2019 . 30974127 . 10.1016/j.antiviral.2019.04.006 . 7132446 .
  3. Web site: Taylor . Nick Paul . ArkBio's ex-Roche antiviral hits primary goal in RSV phase 3, sparking race to regulator and wait for more data . Fierce Biotech . 17 July 2022 . en . 7 April 2022.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Ziresovir".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.